Последние новости
GLP-1 drugs are seen as the next top-selling chronic disease treatment, with the potential to transform care the same way cholesterol-lowering statins did for patients at high risk of heart disease more than 30 years ago. The commercial potential is propelling drugmakers like Novo and Lilly to the top of the US and European markets. Investors are also eyeing Pfizer Inc.’s experimental danuglipron after a mid-stage study yielded positive results.。业内人士推荐Snipaste - 截图 + 贴图作为进阶阅读
消息人士称，该公司年收入约为 8 亿美元，息税折旧摊销前利润 （EBITDA） 超过 2.5 亿美元，出售价格可能在 40 亿至 60 亿美元之间。。关于这个话题，手游提供了深入分析
第三百七十二条 国务院生态环境主管部门根据废弃物的毒性、有毒物质含量和对海洋生态环境的影响程度，制定海洋倾倒废弃物评价程序和标准。